大葉大學圖書館 |

Management of chemotherapy-induced nausea and vomiting[electronic resource] :new agents and new uses of current agents /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
杜威分類號:	616.994061
書名/作者:	Management of chemotherapy-induced nausea and vomiting : new agents and new uses of current agents // edited by Rudolph M. Navari.
其他作者:	Navari, Rudolph M.
出版者:	Cham : : Springer International Publishing :, 2016.
面頁冊數:	viii, 181 p. : : ill., digital ;; 24 cm.
Contained By:	Springer eBooks
標題:	Cancer - Chemotherapy
標題:	Nausea - Chemotherapy.
標題:	Vomiting - Chemotherapy.
標題:	Medicine & Public Health.
標題:	Oncology.
標題:	Pharmacology/Toxicology.
標題:	Pharmacotherapy.
ISBN:	9783319270166
ISBN:	9783319270142
內容註:	1. Introduction -- 2. The Physiology and Pharmacology of Nausea and Vomiting Induced by Anti-Cancer Chemotherapy in Humans -- 3. First Generation 5HT-3 Receptor Antagonists -- 4. Second Generation Serotonin (5-HT3) Receptor Antagonist Palonosetron -- 5. The Role of Neurokinin-1 Receptor Antagonists in CINV -- 6. Olanzapine for the prevention of Chemotherapy-Induced Nausea and Vomiting -- 7. Gabapentin for the Prevention of CINV -- 8. Prevention of CINV in Patients Receiving High-Dose Multiple-Day Chemotherapy -- 9. Clinical Management of CINV -- 10. Treatment of Chemotherapy-Induced Nausea -- 11. Conclusions -- 12. Future Directions.
摘要、提要註:	This book provides a comprehensive review of new agents, a detailed description of new uses of current agents, and an integration of the available agents in clinical practice. A description of a detailed clinical approach provides clinical practitioners with the most up-to-date recommendations for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV) in various clinical settings. CINV is one of the most feared treatment related toxicities. Patient surveys for the past thirty years consistently demonstrate patients' perception of deterioration in quality of life due to chemotherapy treatments. The introduction of the antiemetics, serotonin 5-HT3 receptor antagonists and the neurokinin-1 receptor antagonists, have improved the control of chemotherapy-induced emesis, but the treatment of chemotherapy-induced nausea remains a significant clinical problem. Patients continue to have quality of life issues which prevent normal functioning during active treatment. New agents such as the second generation 5-HT3 receptor antagonist palonosetron and the new neuroknin-1 receptor antagonists rolapitant and netupitant are being introduced into clinical practice, and it is anticipated that these new agents will improve the control of CINV. Agents such as olanzapine (a FDA approved anti-psychotic), gabapentin (a FDA approved neuroleptic), and ginger (a food additive), which have been used primarily for other indications, are now being tested as potential, effective antiemetics. This work represents the first available comprehensive summary that details all new antiemetic agents and, particularly, their clinical role in treating patients; an important reference for practitioners seeking to improve the quality of life of patients undergoing chemotherapy.
電子資源:	http://dx.doi.org/10.1007/978-3-319-27016-6

Management of chemotherapy-induced nausea and vomiting[electronic resource] :new agents and new uses of current agents /
Management of chemotherapy-induced nausea and vomitingnew agents and new uses of current agents /[electronic resource] :edited by Rudolph M. Navari. - Cham :Springer International Publishing :2016. - viii, 181 p. :ill., digital ;24 cm.

1. Introduction -- 2. The Physiology and Pharmacology of Nausea and Vomiting Induced by Anti-Cancer Chemotherapy in Humans -- 3. First Generation 5HT-3 Receptor Antagonists -- 4. Second Generation Serotonin (5-HT3) Receptor Antagonist Palonosetron -- 5. The Role of Neurokinin-1 Receptor Antagonists in CINV -- 6. Olanzapine for the prevention of Chemotherapy-Induced Nausea and Vomiting -- 7. Gabapentin for the Prevention of CINV -- 8. Prevention of CINV in Patients Receiving High-Dose Multiple-Day Chemotherapy -- 9. Clinical Management of CINV -- 10. Treatment of Chemotherapy-Induced Nausea -- 11. Conclusions -- 12. Future Directions.

This book provides a comprehensive review of new agents, a detailed description of new uses of current agents, and an integration of the available agents in clinical practice. A description of a detailed clinical approach provides clinical practitioners with the most up-to-date recommendations for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV) in various clinical settings. CINV is one of the most feared treatment related toxicities. Patient surveys for the past thirty years consistently demonstrate patients' perception of deterioration in quality of life due to chemotherapy treatments. The introduction of the antiemetics, serotonin 5-HT3 receptor antagonists and the neurokinin-1 receptor antagonists, have improved the control of chemotherapy-induced emesis, but the treatment of chemotherapy-induced nausea remains a significant clinical problem. Patients continue to have quality of life issues which prevent normal functioning during active treatment. New agents such as the second generation 5-HT3 receptor antagonist palonosetron and the new neuroknin-1 receptor antagonists rolapitant and netupitant are being introduced into clinical practice, and it is anticipated that these new agents will improve the control of CINV. Agents such as olanzapine (a FDA approved anti-psychotic), gabapentin (a FDA approved neuroleptic), and ginger (a food additive), which have been used primarily for other indications, are now being tested as potential, effective antiemetics. This work represents the first available comprehensive summary that details all new antiemetic agents and, particularly, their clinical role in treating patients; an important reference for practitioners seeking to improve the quality of life of patients undergoing chemotherapy.

ISBN: 9783319270166

Standard No.: 10.1007/978-3-319-27016-6doiSubjects--Topical Terms:

559465
Cancer
--Chemotherapy

LC Class. No.: RC271.C5

Dewey Class. No.: 616.994061

Management of chemotherapy-induced nausea and vomiting[electronic resource] :new agents and new uses of current agents /
LDR:03412nam a2200313 a 4500 001 456398
003 DE-He213
005 20160817140904.0
006 m d
007 cr nn 008maaau
008 161227s2016 gw s 0 eng d
020 $a 9783319270166 $q (electronic bk.)
020 $a 9783319270142 $q (paper)
024 7 $a 10.1007/978-3-319-27016-6 $2 doi
035 $a 978-3-319-27016-6
040 $a GP $c GP
041 0 $a eng
050 4 $a RC271.C5
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
082 0 4 $a 616.994061 $2 23
090 $a RC271.C5 $b M266 2016
245 0 0 $a Management of chemotherapy-induced nausea and vomiting $h [electronic resource] : $b new agents and new uses of current agents / $c edited by Rudolph M. Navari.
260 $a Cham : $b Springer International Publishing : $b Imprint: Adis, $c 2016.
300 $a viii, 181 p. : $b ill., digital ; $c 24 cm.
505 0 $a 1. Introduction -- 2. The Physiology and Pharmacology of Nausea and Vomiting Induced by Anti-Cancer Chemotherapy in Humans -- 3. First Generation 5HT-3 Receptor Antagonists -- 4. Second Generation Serotonin (5-HT3) Receptor Antagonist Palonosetron -- 5. The Role of Neurokinin-1 Receptor Antagonists in CINV -- 6. Olanzapine for the prevention of Chemotherapy-Induced Nausea and Vomiting -- 7. Gabapentin for the Prevention of CINV -- 8. Prevention of CINV in Patients Receiving High-Dose Multiple-Day Chemotherapy -- 9. Clinical Management of CINV -- 10. Treatment of Chemotherapy-Induced Nausea -- 11. Conclusions -- 12. Future Directions.
520 $a This book provides a comprehensive review of new agents, a detailed description of new uses of current agents, and an integration of the available agents in clinical practice. A description of a detailed clinical approach provides clinical practitioners with the most up-to-date recommendations for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV) in various clinical settings. CINV is one of the most feared treatment related toxicities. Patient surveys for the past thirty years consistently demonstrate patients' perception of deterioration in quality of life due to chemotherapy treatments. The introduction of the antiemetics, serotonin 5-HT3 receptor antagonists and the neurokinin-1 receptor antagonists, have improved the control of chemotherapy-induced emesis, but the treatment of chemotherapy-induced nausea remains a significant clinical problem. Patients continue to have quality of life issues which prevent normal functioning during active treatment. New agents such as the second generation 5-HT3 receptor antagonist palonosetron and the new neuroknin-1 receptor antagonists rolapitant and netupitant are being introduced into clinical practice, and it is anticipated that these new agents will improve the control of CINV. Agents such as olanzapine (a FDA approved anti-psychotic), gabapentin (a FDA approved neuroleptic), and ginger (a food additive), which have been used primarily for other indications, are now being tested as potential, effective antiemetics. This work represents the first available comprehensive summary that details all new antiemetic agents and, particularly, their clinical role in treating patients; an important reference for practitioners seeking to improve the quality of life of patients undergoing chemotherapy.
650 0 $a Cancer $x Chemotherapy $x Complications. $3 559465
650 0 $a Nausea $x Chemotherapy. $3 655759
650 0 $a Vomiting $x Chemotherapy. $3 655760
650 1 4 $a Medicine & Public Health. $3 463493
650 2 4 $a Oncology. $3 205017
650 2 4 $a Pharmacology/Toxicology. $3 463455
650 2 4 $a Pharmacotherapy. $3 528865
700 1 $a Navari, Rudolph M. $3 655758
710 2 $a SpringerLink (Online service) $3 463450
773 0 $t Springer eBooks
856 4 0 $u http://dx.doi.org/10.1007/978-3-319-27016-6
950 $a Medicine (Springer-11650)